-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2025-522437-65-00
4
2026-03-06
small-cell lung cancer
-
2024-519622-20-00
1
2026-02-27
Advanced Solid Tumors Harboring RAS Mutation(S)
-
2024-520027-88-00
4
2026-02-12
Patients with hormone receptor-positive (HR+) breast cancer
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2024-518777-34-00
5
2026-02-11
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2022-503140-41-00
5
2025-12-19
Melanoma
-
2023-509124-18-00
5
2025-12-19
Moderate-to-Severe Atopic Dermatitis
-
2024-510778-26-00
4
2025-12-19
Metastatic Non-Small-Cell Lung Cancer
-
2024-518899-31-00
5
2025-12-19
Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
-
2025-520979-13-00
5
2025-12-18
Patients with HR+ HER2- early breast cancer at intermediate risk of re
-
2025-521299-76-00
7
2025-12-18
Relapsed or refractory acute leukaemia or Myelodysplastic Syndromes wi
-
2025-522455-26-00
9
2025-12-17
Acute Ischemic Stroke
-
2025-521276-59-00
5
2025-12-16
Autosomal dominant polycystic kidney disease (ADPKD)
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2025-520794-39-00
5
2025-12-10
Arterial Hypertension
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2025-521034-28-00
4
2025-12-05
Moderate to Severe Rheumatoid Arthritis (RA)
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2024-512922-27-00
4
2025-11-25
Mantle Cell Lymphoma (MCL)